Blockchain Registration Transaction Record

Aclarion and Weill Cornell Launch Second Spine Trial with Nociscan

Aclarion partners with Weill Cornell Medicine for second Nociscan trial led by Dr. Roger Härtl, studying BMAC injections for degenerative disc disease to improve chronic low back pain treatment.

Chronic low back pain affects 266 million people worldwide, yet identifying the exact pain source remains a challenge. This trial could revolutionize treatment by combining Nociscan's biomarker-based pain localization with BMAC injections, potentially offering a less invasive, more effective option for degenerative disc disease. If successful, it may reduce failed back surgeries and improve quality of life for millions.